



## International Journal of Chemistry and Pharmaceutical Sciences

IJCPS, 2013: Vol.1(6): 433-441

[www.pharmaresearchlibrary.com/ijcps](http://www.pharmaresearchlibrary.com/ijcps)

### Simultaneous Estimation of Amlodipine and Atenolol by Using Reverse Phase High Performance Liquid Chromatography in Bulk and Marketed Formulation

Devanapelly Shashikantha Rao\*

*Lecturer, Department of Chemistry, C.K.M. Arts and Science College, Warangal- 506006, Andhra Pradesh, India.*\*E-mail: [shashikanth.dev@gmail.com](mailto:shashikanth.dev@gmail.com)

Available Online 27 October 2013

#### Abstract

A simple precise and accurate reverse phase high performance liquid chromatography (RP-HPLC) method has been developed for the simultaneous estimation of Amlodipine and Atenolol. Chromatographic separation was achieved on Altima C<sub>18</sub> column (4.6×150mm, 5μ) using the mobile phase consisting of Methanol: TEA buffer: ACN (50:25:25 v/v). The mobile phase was pumped at a flow rate of 1.0 mL/min and detection was done by UV detector at 225 nm. The retention time for Amlodipine and Atenolol was 2.102 min and 3.577 min. The linearity concentrations for Amlodipine and Atenolol was 5-25 μg/ml and 12.5-62.5 μg/ml respectively with correlation coefficient was found to be 0.999. The proposed method was found to be simple, accurate, precise and cost effective for the simultaneous estimation of Amlodipine and Atenolol in pharmaceutical dosage forms.

**Keywords:** Amlodipine, Atenolol, RP-HPLC, Mobile phase, TEA Buffer

#### INTRODUCTION

Amlodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation<sup>1,2</sup>. Atenolol, a competitive beta (1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. It competes with sympathomimetic neurotransmitter such as catecholamine's for binding at beta (1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension<sup>3-5</sup>.




Fig 1: Structure of Amlodipine




Fig 2: Structure of Atenolol

Literature survey reveals that few spectrophotometric and chromatographic methods have been reported for the estimation of Amlodipine and Atenolol in single and combination with other drugs<sup>8-14</sup>. Therefore an attempt has been made to develop and validate simple, precise and accurate RP-HPLC method for simultaneous estimation of Amlodipine and Atenolol in combined dosage form.

## MATERIALS AND METHODS

### Instrument used:

The liquid chromatographic system consists of Waters HPLC with auto sampler and PDA Detector 996 model. Chromatographic analysis was performed on Altima C18 (4.6×150mm, 5 $\mu$ ) column. The analytes were monitored at 225 nm.

### Materials used:

Working standards of Amlodipine and Atenolol were procured as a gift sample by Sura labs, Hyderabad, India. Formulation of Amlodipine and Atenolol combined dosage form was purchased from local pharmacy. HPLC grade methanol, water and Acetonitrile was purchased from E. Merck (India) Ltd., Mumbai, India. AR Grade Triethylamine buffer was obtained from S.D. Fine Chemicals Ltd., Mumbai, India.

### Optimized Chromatographic Conditions:

Instrument used : Waters HPLC with auto sampler and PDA Detector 996 model.  
Temperature : 40°C  
Column : Altima C18 (4.6×150mm, 5 $\mu$ )  
Buffer : Dissolve 1.5ml of Triethylamine in 250 ml HPLC water and adjust the pH 4.5. Filter and sonicate the solution by vacuum filtration and ultra sonication.  
pH : 4.5  
Mobile phase : Methanol: TEA buffer: ACN (50:25:25 v/v)  
Flow rate : 1ml/min  
Wavelength : 225 nm  
Injection volume : 10  $\mu$ l  
Run time : 7 min




Fig 3: Optimized Chromatogram

### Preparation of mobile phase:

Accurately measured 400 ml (40%) of Methanol, 200 ml of Triethylamine buffer (20%) and 400 ml of Acetonitrile (40%) were mixed and degassed in digital ultra sonicator for 10 minutes and then filtered through 0.45  $\mu$  filter under vacuum filtration.

**Preparation of Standard Solution:**

Accurately weigh and transfer 10 mg of Amlodipine and 10mg of Atenolol working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution). Further pipettes 0.1ml of the above Amlodipine and 0.375ml of the Atenolol stock solutions into a 10ml volumetric flask and dilute up to the mark with Diluent.

**Preparation of Sample Solution:**

Take average weight of one Tablet and crush in a mortar by using pestle and weight 10 mg equivalent weight of Amlodipine and Atenolol sample into a 10mL clean dry volumetric flask and add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. Further pipette 0.1ml of the above Amlodipine and 0.375ml of the Atenolol stock solutions into a 10ml volumetric flask and dilute up to the mark with Diluent.

## RESULTS AND DISCUSSION

**Method validation**

The developed analytical method was validated as per ICH guidelines for the parameters like specificity, linearity, accuracy, precision, robustness and system suitability.

**System Suitability**

Accurately weigh and transfer 10 mg of Amlodipine and 10mg of Atenolol working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent (Stock solution). Further pipette 0.1ml of the above Amlodipine and 0.375ml of the Atenolol stock solutions into a 10ml volumetric flask and dilute up to the mark with Diluent.

**Procedure:**

The standard solution was injected for five times and measured the area for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be within the specified limits. The results were shown in table 1.

**Specificity**

Inject the three replicate injections of standard and sample solutions and calculate the assay by using formula:

$$\% \text{ ASSAY} = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

The % purity of Amlodipine and Atenolol in pharmaceutical dosage form was found to be 99.6%. Results were shown in table 2 and fig 4,5.

**Linearity**

Accurately weigh and transfer 10 mg of Amlodipine and 10mg of Atenolol working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

**Preparation of Level – I (5 ppm of Amlodipine & 12.5ppm of Atenolol):**

Pipette out 0.05ml of Amlodipine and 0.125ml of Atenolol stock solutions was take in a 10ml of volumetric flask dilute up to the mark with diluent.

**Preparation of Level – II (10 ppm of Amlodipine & 25ppm of Atenolol):**

Pipette out 0.1ml of Amlodipine and 0.25ml of Atenolol stock solutions was take in a 10ml of volumetric flask dilute up to the mark with diluent.

**Preparation of Level – III (15 ppm of Amlodipine & 37.5ppm of Atenolol):**

Pipette out 0.15 ml of Amlodipine and 0.375ml of Atenolol stock solutions was take in a 10ml of volumetric flask dilute up to the mark with diluent.

**Preparation of Level – IV (20 ppm of Amlodipine & 50ppm of Atenolol):**

Pipette out 0.2 ml of Amlodipine and 0.5ml of Atenolol stock solutions was take in a 10ml of volumetric flask dilute up to the mark with diluent.

**Preparation of Level – V (25 ppm of Amlodipine & 62.5ppm of Atenolol):**

Pipette out 0.25ml of Amlodipine and 0.625ml of Atenolol stock solutions was take in a 10ml of volumetric flask dilute up to the mark with diluent.

**Procedure:**

Inject each level into the chromatographic system and measure the peak area. Plot a graph of peak area versus concentration (on X-axis concentration and on Y-axis Peak area) and calculate the correlation coefficient. Results were shown in table 3 and fig 6,7.

**Precision**

**Preparation of Amlodipine and Atenolol Product Solution for Precision:** Accurately weigh and transfer 10 mg of Amlodipine and 10mg of Atenolol working standard into a 10ml of clean dry volumetric flasks add about 7mL of

Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent (Stock solution). Further pipette 0.1ml of the above Amlodipine and 0.375ml of the Atenolol stock solutions into a 10ml volumetric flask and dilute up to the mark with Diluent. The standard solution was injected for five times and measured the area for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be within the specified limit. Results were shown in table 4.

#### Accuracy

##### For preparation of 50% Standard stock solution:

Accurately weigh and transfer 10 mg of Amlodipine and 10mg of Atenolol working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent (Stock solution). Further pipette 0.075ml of the above Amlodipine and 0.187ml of the Atenolol stock solutions into a 10ml volumetric flask and dilute up to the mark with Diluent.

##### For preparation of 100% Standard stock solution:

Accurately weigh and transfer 10 mg of Amlodipine and 10mg of Atenolol working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent (Stock solution). Further pipette 0.15ml of the above Amlodipine and 0.375ml of the Atenolol stock solutions into a 10ml volumetric flask and dilute up to the mark with Diluent.

##### For preparation of 150% Standard stock solution:

Accurately weigh and transfer 10 mg of Amlodipine and 10mg of Atenolol working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent (Stock solution). Further pipette 0.225ml of Amlodipine and 0.56ml of Atenolol from the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

#### Procedure:

Inject the Three replicate injections of individual concentrations (50%,100%,150%) were made under the optimized conditions. Recorded the chromatograms and measured the peak responses. Calculate the Amount found and Amount added for Amlodipine and Atenolol and calculate the individual recovery and mean recovery values. Results were shown in table 5.

#### Robustness

The analysis was performed in different conditions to find the variability of test results. The following conditions are checked for variation of results. .

##### Effect of Variation of flow conditions:

The sample was analyzed at 0.9 ml/min and 1.1 ml/min instead of 1ml/min, remaining conditions are same. 10 $\mu$ l of the above sample was injected and chromatograms were recorded.

##### Effect of Variation of mobile phase organic composition:


The sample was analyzed by variation of mobile phase i.e. Methanol: TEA Buffer: Acetonitrile was taken in the ratio and 40: 40:20, 60:10:30 instead (50:25:25), remaining conditions are same. 10 $\mu$ l of the above sample was injected and chromatograms were recorded. Results were shown in table 7.

**Table 1: Results for System suitability**


| Sl.no.                                  | Characteristic       | Amlodipine | Atenolol |
|---|----------------------|------------|----------|
| 1.                                      | Retention time (min) | 2.102      | 3.577    |
| 1                                       | Tailing factor       | 1.6        | 1.4      |
| 2                                       | Theoretical plates   | 5377.2     | 5535.6   |
| 3                                       | Resolution           | 2.02       |          |
| *Number of injections = Five replicates |                      |            |          |

**Table 2: Results for Specificity**

| S.No             | Standard   |          | Sample     |          |
|------------------|------------|----------|------------|----------|
|                  | Amlodipine | Atenolol | Amlodipine | Atenolol |
| 1                | 607323     | 558777   | 775610     | 555592   |
| 2                | 606379     | 578377   | 689956     | 575685   |
| 3                | 606885     | 556966   | 607323     | 558777   |
| Assay (% Purity) | 99.6       |          |            |          |




**Fig 4: Chromatogram for Standard**



**Fig 5: Chromatogram for Sample**

**Table 3: Results for linearity**

| Amlodipine                        |           | Atenolol                          |           |
|-----------------------------------|-----------|-----------------------------------|-----------|
| Concentration( $\mu\text{g/ml}$ ) | Peak area | Concentration( $\mu\text{g/ml}$ ) | Peak area |
| 5                                 | 205035    | 12.5                              | 757881    |
| 10                                | 381239    | 25                                | 757881    |
| 15                                | 561128    | 37.5                              | 1458941   |
| 20                                | 740162    | 50                                | 2132457   |
| 25                                | 909922    | 62.5                              | 2901811   |



**Fig 6: Calibration graph for Amlodipine**




Fig 7: Calibration graph for Atenolol

Table 4: Results for Precision

| S.no | Amlodipine |           | Atenolol  |           |
|------|------------|-----------|-----------|-----------|
|      | Intra day  | Inter day | Intra day | Inter day |
| 1    | 602223     | 596608    | 2220333   | 2207732   |
| 2    | 607748     | 598959    | 2221573   | 2202266   |
| 3    | 607302     | 595728    | 2215483   | 2209375   |
| 3    | 608674     | 594485    | 2217379   | 2204037   |
| 5    | 607376     | 595267    | 2211255   | 2204466   |
| Avg  | 606665     | 596209    | 2217205   | 2205575   |
| STD  | 2542.3     | 1718.7    | 4100.8    | 2899.8    |
| %RSD | 0.42       | 0.29      | 0.18      | 0.13      |

Table 5: Results for accuracy

| Sample     | Amount added (µg/ml) | Amount Recovered (µg/ml) | Recovery (%) | %Mean Recovery |
|------------|----------------------|--------------------------|--------------|----------------|
| Amlodipine | 7.5                  | 7.56                     | 100.8        | 99.6%          |
| Amlodipine | 15                   | 14.8                     | 98.6         |                |
| Amlodipine | 22.5                 | 22.4                     | 99.5         |                |
| Atenolol   | 18.75                | 18.73                    | 100%         | 100%           |
| Atenolol   | 37.5                 | 37.4                     | 99.9%        |                |
| Atenolol   | 56.25                | 56.21                    | 100%         |                |

Table 6: results for LOD @ LOQ

| Drug       | LOD(µg/ml) | LOQ(µg/ml) |
|------------|------------|------------|
| Amlodipine | 0.2        | 0.8        |
| Atenolol   | 2.3        | 7.04       |

Table 7: Results for Robustness

| Robust condition               | Amlodipine     |                    |                | Atenolol       |                    |                |
|--------------------------------|----------------|--------------------|----------------|----------------|--------------------|----------------|
|                                | Retention Time | Theoretical plates | Tailing factor | Retention Time | Theoretical plates | Tailing factor |
| Actual Flow rate of 1.0 mL/min | 2.102          | 5586               | 1.7            | 3.537          | 5371               | 1.6            |
| Less Flow rate of 0.9 mL/min   | 2.330          | 5231               | 1.7            | 3.885          | 5324               | 1.7            |

|                              |       |      |     |       |      |     |
|------------------------------|-------|------|-----|-------|------|-----|
| More Flow rate of 1.1 mL/min | 1.950 | 5234 | 1.7 | 3.263 | 5098 | 1.7 |
| Less organic phase           | 2.290 | 5643 | 1.4 | 4.435 | 5239 | 1.2 |
| More organic phase           | 1.998 | 5298 | 1.5 | 3.009 | 5647 | 1.0 |

**Table 1: Analytical data of the Schiff base ligand and its mononuclear metal complexes**

| Compound | Molecular Formula                                       | color       | Yield % | Melting Point (°) | % of Nitrogen |       | % of Metal |       | Molar conductance <sub>m</sub> (scm <sup>2</sup> mol <sup>-1</sup> ) |
|----------|---|-------------|---------|-------------------|---------------|-------|------------|-------|--|
|          |   |             |         |                   | Cal           | Exp   | Cal        | Exp   |  |
| L        | C <sub>16</sub> H <sub>15</sub> N <sub>2</sub> OS       | Yellow      | 80      | 140               | 9.88          | 9.86  | -          | -     | -  |
| [CuLX]   | [Cu(C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> OS)] | Dark Green  | 70      | >200              | 11.15         | 11.14 | 12.64      | 12.63 | 132  |
| [NiLX]   | [Ni(C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> OS)] | Brown Black | 75      | >200              | 11.26         | 11.23 | 11.80      | 11.79 | 145  |
| [CoLX]   | [Co(C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> OS)] | Brown       | 70      | >200              | 11.25         | 11.23 | 11.83      | 11.82 | 148  |

**IR spectra**

The IR spectra provide valuable information regarding the coordinating sites of Schiff base ligand which has been already discussed by Raman et al<sup>[9]</sup>. The IR spectra of the complexes were compared with that of the free ligand to determine the changes that might have taken place during the complexation. A comparative study of the IR spectra of ligand and its metal complexes reveals that certain peaks are common and therefore, only important peaks, which have either shifted or have newly appeared, are discussed. Table 2 shows that (C-O) and (C=N) modes occur at 1224-1332 cm<sup>-1</sup> and 1595-1620 cm<sup>-1</sup> respectively.

The shifting of (C-O) towards higher frequency as compared to the ligand (1224 cm<sup>-1</sup>) is due to the conversion of hydrogen bonded structure into a covalent metal bonded structure. Lowering of (C=N) in the complexes as compared to the ligand (1620 cm<sup>-1</sup>) is due to reduction of double bond character of carbon-nitrogen bond of the azomethine group. The band at 1440 cm<sup>-1</sup> and 1522 cm<sup>-1</sup> were due to symmetric stretching frequency and asymmetric frequency of acetate ion. This result predicts that the acetate ions were coordinated outside the coordination sphere. Metal-ligand bond is further confirmed by the appearance of a medium intensity band in the range 444-468, 402-410 and 530-560 cm<sup>-1</sup> in the spectra of the complexes assigned to stretching frequencies of (M-N) bond, (M-S) bond and metal-oxygen bond formation respectively<sup>[10]</sup>.

**Table 2: Infrared Spectroscopic Data of the Schiff Base Ligand and its mononuclear metal complex**

| Compounds   | (C=N) (cm <sup>-1</sup> ) | (C-S) (cm <sup>-1</sup> ) | (C-O) (cm <sup>-1</sup> ) | (M-N) (cm <sup>-1</sup> ) | (M-O) (cm <sup>-1</sup> ) | (M-S) (cm <sup>-1</sup> ) |
|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| C <sub>16</sub> H <sub>15</sub> N <sub>2</sub> OS       | 1620                      | 730                       | 1244                      | --                        | --                        | --                        |
| [Cu(C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> OS)] | 1605                      | 710                       | 1288                      | 460                       | 530                       | 406                       |
| [Ni(C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> OS)] | 1609                      | 744                       | 1320                      | 454                       | 544                       | 410                       |
| [Co(C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> OS)] | 1595                      | 752                       | 1332                      | 468                       | 560                       | 408                       |
| [Mn(C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> OS)] | 1600                      | 718                       | 1324                      | 444                       | 553                       | 402                       |

**Electronic spectra and magnetic moment**

The electronic spectral data of the metal complexes in DMF solution are displayed in Table 3. The nature of the ligand field around the metal ion was deduced from the electronic spectra. The electronic spectrum of Co(II) complex exhibited three bands in the region of 660, 570 and 530 nm which were tentatively assigned to <sup>4</sup>T<sub>1g</sub> <sup>4</sup>T<sub>2g</sub>(F) ( <sub>1</sub> ), <sup>4</sup>T<sub>1g</sub> <sup>4</sup>A<sub>2g</sub>(F) ( <sub>2</sub> ) and <sup>4</sup>T<sub>1g</sub> <sup>4</sup>T<sub>1g</sub>(P) ( <sub>3</sub> ) transitions, respectively. The value of magnetic moment was 5.12 B.M. which indicates the presence of Co(II) complex in octahedral geometry<sup>[11]</sup>. The electronic spectrum of the Ni(II) complex showed three bands at 695, 542 and 575 nm assignable to <sup>3</sup>A<sub>2g</sub> <sup>3</sup>T<sub>2g</sub>(F) ( <sub>1</sub> ), <sup>3</sup>A<sub>2g</sub> <sup>3</sup>T<sub>1g</sub>(F) ( <sub>2</sub> ) and <sup>3</sup>A<sub>2g</sub> <sup>3</sup>T<sub>1g</sub>(P) ( <sub>3</sub> ) transitions, respectively. The value of magnetic moment was 3.42 B.M; therefore octahedral geometry is suggested for this complex<sup>[12]</sup>.

The <sup>2</sup>E<sub>g</sub> and <sup>2</sup>T<sub>2g</sub> states of the octahedral Cu(II) (d<sup>9</sup>) split under the influence of the tetragonal distortion and the distortion can be such as to cause the three transitions <sup>2</sup>B<sub>1g</sub> <sup>2</sup>B<sub>2g</sub>; <sup>2</sup>B<sub>1g</sub> <sup>2</sup>E<sub>g</sub> and <sup>2</sup>B<sub>1g</sub> <sup>2</sup>A<sub>1g</sub> to remain unresolved in the spectra. It is concluded that, all three transitions 690, 570 and 535 nm lie within the single broad envelope centered at the same range previously mentioned. This assignment is in agreement with the general observation that Cu(II) d-d transitions are normally close in energy. The magnetic moment of 1.97 B.M. falls within

the range normally observed for octahedral Cu(II) complexes<sup>[13]</sup>. The electronic spectra of Mn(II) complexes show the absorption bands in the range 694, 555 and 522 nm. These absorption bands may be assigned to the  ${}^6A_{1g} \rightarrow {}^4A_{1g}$ ,  ${}^6A_{1g} \rightarrow {}^4A_{2g}$ , and  ${}^6A_{1g} \rightarrow {}^4E_g$ ,  ${}^4A_{1g}$  transitions, respectively. These bands suggest that the complexes possess an octahedral geometry. The Mn(II) complex show magnetic moments is 5.92 B.M. at room temperature corresponding to five unpaired electrons which suggest octahedral geometry<sup>[14]</sup>. In the spectra of the Schiff base ligand, the absorption band observed at 281-294 nm were assigned to intra-ligand  $\pi \rightarrow \pi^*$  transition and the band at 342-390 nm were assigned due to  $n \rightarrow \pi^*$  transition associated with the azomethine chromophore ( $-C=N$ ).

**Table 3: Electronic Spectral data of Schiff base ligand and its complexes.**

| Compound                  | Electronic spectra (nm) |                       |     |             | Geometry of the complex |
|---------------------------|-------------------------|-----------------------|-----|-------------|-------------------------|
|                           | $\pi \rightarrow \pi^*$ | $n \rightarrow \pi^*$ | L M | d-d         |                         |
| $C_{16}H_{15}N_2OS$       | 294                     | 386                   | -   | -           | -                       |
| $[Cu(C_{26}H_{22}N_4OS)]$ | 285                     | 374                   | 480 | 690,570,535 | Octahedral              |
| $[Ni(C_{26}H_{22}N_4OS)]$ | 292                     | 390                   | 440 | 695,542,575 |                         |
| $[Co(C_{26}H_{22}N_4OS)]$ | 281                     | 342                   | 445 | 660,570,530 |                         |
| $[Mn(C_{26}H_{22}N_4OS)]$ | 293                     | 346                   | 430 | 694,555,522 |                         |

### <sup>1</sup>H NMR spectra

The <sup>1</sup>H NMR Schiff base was recorded in DMSO-  $d_6$  at room temperature. Three different type of protons were identified i) resonance exhibits due to phenolic -OH protons around 10.26 ppm, ii) characteristic resonance due to azomethine proton in the Schiff base appears at 8.227 ppm was observed and iii) the other signals in the region 6.24–7.72 ppm exhibits due to aromatic protons. All these observations support the infrared conclusions.

### EPR spectra

The EPR spectra of complexes provide information of importance in studying the metal ion environment. The EPR spectra of the  $[Cu(C_{26}H_{22}N_4OS)]$  Schiff base complexes recorded on powder samples with room temperature, on X-band at frequency 9.3 GHz under the magnetic field strength 4000 G. The EPR spectrum of the  $[Cu(C_{26}H_{22}N_4OS)]$  (Figure 2) complexes show a broad signal with  $g_{iso}$  at 1.9998 which is consistent with an octahedral geometry<sup>[15]</sup>.



**Figure.2.EPR spectra of Cu ( $C_{26}H_{22}N_4OS$ ) complex**

### CONCLUSION

In the present investigation, a simple, sensitive, precise and accurate RP-HPLC method was developed for the quantitative estimation of Amlodipine and Atenolol in bulk drug and pharmaceutical dosage forms. This method was simple, since diluted samples are directly used without any preliminary chemical derivatisation or purification steps. Amlodipine and Atenolol was freely soluble in ethanol, methanol and sparingly soluble in water. Methanol: TEA Buffer pH 4.5: Acetonitrile (50:25:25) was chosen as the mobile phase. The solvent system used in this method was economical. The %RSD values were within 2 and the method was found to be precise. The results expressed in Tables for RP-HPLC method was promising. The RP-HPLC method is more sensitive, accurate and precise compared to the Spectrophotometric methods. This method can be used for the routine determination of Amlodipine and Atenolol in bulk drug and in Pharmaceutical dosage forms.

## REFERENCES

- [1] Bosch E, Espinosa S, Roses M. Retention of ionisable compounds on high performance liquid chromatography: III. Variation of pKa values of acids and pH values of buffers in acetonitrile–water mobile phases. *J. Chromatogr. A*. 1998; 824(2): 137–146.
- [2] Bosch E, Bou P, Allemann H, *et al.* Retention of ionisable compounds on HPLC: pH scale in methanol–water and the pKa and pH values of buffers. *J. Anal. Chem.* 1996; 68(20): 3651–3657.
- [3] Kupiec T. Quality control analytical methods: high-performance liquid chromatography. *Int. J. Pharma. Compound.* 2004; 8(3): 223-227.
- [4] Md. Ahsanul Haque , Asma Naznin , A.N.M Hamidul Kabir, Md. Khalid Hossain and S.M. Ashraful Islam Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Atenolol and Amlodipine in Tablet Dosage Form. *Dhaka Univ. J. Pharm. Sci.* 9(2): 131-138, 2010 (December)
- [5] Abdussaleem.K, D.Boopathy, P.Perumal Analytical Method Development and Validation of Losartan Potassium and Atenolol in combined dosage form by RP-HPLC. *Int.J. Pharm Tech Res.* 2010, 2(1).
- [6] Sohan S Chitlange, Mohammed Imran, Dinesh M Sakarkar, RP-HPLC method for simultaneous estimation of amlodipine and metoprolol in tablet formulation. *Asian Journal of Pharmaceutics*, 2008, 232-234.
- [7] *Indian Pharmacopoeia*, Vol. 1. New Delhi: Government of India, the Controller of Publication; 1996. p. 387-9.
- [8] Veeraskaran V, Katakdhond SJ, Kadam SS, Jadhvi RR. Simultaneous spectrophotometric estimation of hydrochlorothiazide and metoprolol tartarate from combined dosage form. *Indian Drug* 2001; 38: 187.
- [9] Pai PN, Shenoy KR, Pandey J. Simultaneous reverse phase liquid chromatographic determination of metoprolol tartarate and hydrochlorothiazide in tablets., *Indian J Pharma Sci* 2005;67:608-10.
- [10] Qin LI, Rui W. Simultaneous analysis of tramadol, metoprolol and their metabolites in human plasma and urine by HPLC. *Chinese Med J* 2006; 119: 2013-7.
- [11] Chiu FC, Damani LA, Li RC, Tomlinson B. Efficient high-performance liquid chromatographic assay for the simultaneous determination of metoprolol and two main metabolites in human urine by solid-phase extraction and fluorescence detection. *J Chromatogr B Biomed Sci Appl* 1997; 696: 69-74.
- [12] Chawla S, Ghosh S, Sihorkar V, Nellore R, Kumar TR, Srinivas NR. High-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detection. *Biomed Chromatogr.* 2005;20:349-57.
- [13] Salem H, Abdallah OM. Determination of metoprolol and felodipine in binary mixture using chemometric-assisted spectrophotometric and high-performance liquid chromatographic-UV methods. *Am J Appl Sci* 2007, 4: 709.
- [14] Rontogianni MA, Markopoulou CK, Koundourellis JE. HPLC and chemometrically-assisted spectrophotometric estimation of two binary mixtures for combined hypertension therapy. *J Liquid Chromatogr Related Technol* 2006, 29: 2701-19.
- [15] Maria PQ, Anna MB, Luciano M, Guiseppe F, Fabio T. Simultaneous determination of propranolol or metoprolol in the presence of butyrophenones in human plasma by gas chromatography with mass spectrometry. *J Pharm Sci* 1993, 82: 187-90.
- [16] Gowda KV, Mandal U, Selvan PS, Solomon WD, Ghosh A, Sarkar AK, *et al.* Liquid chromatography tandem mass spectrometry method for simultaneous determination of metoprolol tartrate and ramipril in human plasma. *J Chromatogr* 2007, 858:13-21.
- [17] Ranjan Kumar Barman, m. Anwar ul islam , Maruf Ahmed , Mir Imam Ibne Wahed, Robiul Islam, Alam Khan , m. Belal hossain and Bytul M Rahman. Simultaneous High-Performance Liquid Chromatographic Determination Of Atenolol And Amlodipine in Pharmaceutical-Dosage Form. *Pak. J. Pharm. Sci.*, 2007, Vol.20 (4), 274-279.